Clarient Diagnostic Services

Featured Customer

We've seen a 35% improvement in our cash collections over the short two year period that we've had the XIFIN product up and running and validated. It's been a very important tool for us to really improve the financial health of our company.

Ron Andrews
Former CEO, Clarient Inc., a NeoGenomics Company

Success Story

Clarient Diagnostic Services, a NeoGenomics Company, discusses how XIFIN RPM improved its collections and financial reporting.

Clarient is a specialty molecular biology laboratory that is dedicated to cancer diagnostics and testing. Clarient combines innovative diagnostic technologies with world-class pathology expertise to assess and characterize cancer, with a mission to translate cancer discovery and research into better patient care. In this video series, Clarient co-founder Ron Andrews and former vice president of finance Glen Fredenberg discuss the benefits Clarient received from using XIFIN's lab billing solutions.

Clarient was a relatively small public company that was growing rapidly, and the management team was investing in critical resources and infrastructure to support the company's growth. Clarient was using an outsourced billing process. As a public company, accurate financial reporting is critical, and with the outsourced billing process Clarient lacked transparency and granular visibility into payor behavior. So the team decided to bring the billing system in-house.

Clarient chose XIFIN's Revenue Cycle Management solution based on a number of factors. First, the management team appreciated the cost model and ease of set-up with XIFIN RPM, which did not place a resource burden on a Clarient team that was already stretched thin through its efforts to keep up with the rapid growth. XIFIN RPM fit most of the company's needs straight away and was easily tailored to fit any unique requirements.The Clarient team recognized that the XIFIN solution was built by a team that truly understood its business.

With XIFIN, Clarient saw cash collections increase 35%. For the first time, Clarient's finance team had clarity around the billing and collection process. The company achieved increased confidence in its financial reporting, and credits this confidence in leading to its high market valuation, which led to its acquisition first by GE Healthcare, then by NeoGenomics. Clarient continues to have the data needed to more accurately forecast revenue, set loss reserves, and proactively identify opportunities to accelerate the collection process.


Clarient Diagnostic Services (a NeoGenomics Company)

Clarient combines innovative diagnostic technologies with world-class pathology expertise to assess and characterize cancer. NeoGenomics is a premier cancer diagnostics and pharma services company serving oncologists, pathologists, pharmaceutical companies, academic centers, and others with innovative diagnostic, prognostic and predictive testing. Its vision embodies uncompromising quality, exceptional service, and innovative solutions. NeoGeonomics has a network of CAP-accredited, CLIA-licensed facilities across the U.S., but works hard to maintain easy access and all the efficiencies of a smaller operation. NeoGenomics has been serving the cancer community for over 12 years, and welcomed Clarient Diagnostic Services through acquisition of that company in December 2015.

Aliso Viejo, CA
Organization Type:
Anatomic Pathology, Molecular Diagnostics
XIFIN Solution:
Revenue Cycle Management
Chrome 58 or later, Firefox 52 or later, Internet Explorer 11 Microsoft Window 7 or later operating system Healthcare